Methylprednisolone Acetate Shortage: FDA Alert & Compliance

FDA Drug Shortage Alert: Methylprednisolone Acetate Injection Due to Demand Surge

FDA added methylprednisolone acetate injectable suspension (40 mg/mL and 80 mg/mL vials) to the drug shortage list on January 13, 2025, citing increased demand as the primary driver. Wholesale distributors must immediately assess inventory allocations and prepare for potential supply chain disruptions affecting specialty pharmacy customers treating autoimmune and inflammatory conditions.

Regulatory Context

Drug shortages fall under FDA's authority pursuant to Section 506E of the Federal Food, Drug, and Cosmetic Act, as amended by the FDA Safety and Innovation Act (FDASIA) of 2012. FDA maintains a public drug shortage database accessible via the Center for Drug Evaluation and Research (CDER) website. When a shortage is declared, FDA coordinates with manufacturers to prevent or mitigate supply disruptions but does not control allocation—that remains a commercial decision between manufacturers and distributors.

Under 21 CFR Part 314.81(b)(3)(iii), manufacturers must notify FDA at least six months prior to a discontinuation or interruption in manufacturing that could lead to a shortage. The methylprednisolone acetate shortage was not triggered by manufacturing cessation but by demand exceeding current production capacity—a scenario where advance notification is not mandated but voluntary manufacturer cooperation is expected.

Key Details

Product Affected:

Methylprednisolone acetate injectable suspension, 40 mg/mL and 80 mg/mL single-dose and multi-dose vials. This is a corticosteroid used for intra-articular, intralesional, and soft tissue injection in the treatment of inflammatory and autoimmune conditions including rheumatoid arthritis, osteoarthritis, bursitis, and allergic reactions.

Shortage Status (as of January 13, 2025):

• FDA classifies this as an active shortage
• Reason: Increased demand
• No manufacturing quality issues or recalls cited
• Current supply available but insufficient to meet demand
• No estimated resolution date provided by FDA or manufacturers

Affected Manufacturers:

FDA lists multiple manufacturers of methylprednisolone acetate injection under NDC listings, including Pfizer (formerly Pharmacia & Upjohn), Fresenius Kabi USA, and others. Manufacturer-specific availability data is not disclosed in FDA shortage reports.

Alternative Products:

FDA does not list therapeutic alternatives in the shortage database. Clinical alternatives may include oral methylprednisolone tablets, prednisolone sodium phosphate injection, or triamcinolone acetonide injection, but substitution requires prescriber consultation.

Impact on Wholesale Distributors and 3PLs

Immediate Inventory Actions Required:

Distributors holding existing methylprednisolone acetate inventory face allocation decisions. Entities licensed under 21 CFR Part 205 (prescription drug wholesale distributors) must ensure allocation practices do not violate state and federal prohibitions on hoarding or market manipulation. Forty-nine states and DC have anti-price gouging statutes that may apply during declared shortages, though federal shortage declarations do not automatically trigger state statutes.

Customer Communication Obligations:

Specialty pharmacies and hospital systems relying on just-in-time methylprednisolone acetate delivery will contact distributors seeking volume guarantees. Wholesale distributors should document allocation methodologies (e.g., historical purchase ratios, tier-based allocation) to demonstrate non-discriminatory practices in the event of post-shortage audits or legal disputes.

Cold Chain Considerations:

Methylprednisolone acetate injection requires storage at controlled room temperature (20-25°C / 68-77°F per USP). This is not a refrigerated product, but 3PLs with existing methylprednisolone acetate stock should verify storage conditions are maintained during the shortage period to prevent additional supply loss due to temperature excursions.

DSCSA Transaction Documentation:

Increased demand may drive secondary market activity. Distributors must ensure all Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) documentation is complete for any methylprednisolone acetate units transferred during the shortage period, per 21 USC 360eee-1(b). Gray market or unauthorized distributors may attempt to exploit the shortage—trading partners should verify NABP accreditation or state licensure before accepting offers.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these, 1,234 (96.8%) hold active FDA establishment registration—a baseline requirement for entities distributing prescription drugs like methylprednisolone acetate. However, only 63 entities (4.9%) hold NABP accreditation, the industry's voluntary third-party verification of compliance with DSCSA and state licensure requirements.

The average compliance score across all tracked entities is 51/100, placing the majority in the "Fair" tier. This means most distributors have verifiable state licenses and FDA registration but lack additional compliance signals such as NABP accreditation, cGMP certifications, or clean enforcement records. During shortage periods, procurement teams often expand their approved trading partner lists—introducing higher risk if vetting standards are relaxed.

Score Distribution Context for Shortage Response:

• 28 entities (2.2%) score in the Excellent range (76-100 pts): These entities hold broad state licensure, NABP accreditation, and clean enforcement records—lowest-risk trading partners during supply disruptions.
• 281 entities (22.0%) score Good (61-75 pts): Likely candidates for secondary sourcing, pending individual due diligence.
• 919 entities (72.1%) score Fair (41-60 pts): Require additional verification before onboarding as new methylprednisolone acetate sources.
• 47 entities (3.7%) score Poor or Minimal (0-40 pts): High-risk profiles with limited verifiable compliance data—not recommended during shortage scenarios when supply chain scrutiny increases.

Practical Guidance for QA and Procurement Teams

Immediate Actions:

• Verify current trading partners: Use the ColdChainCheck directory to confirm FDA registration status and state licensure for existing methylprednisolone acetate suppliers. Filter by state (distributor location) and check for recent enforcement actions or recalls.

• Pre-qualify backup distributors: Identify 2-3 alternative distributors in your region with compliance scores ≥61 and active licenses in your jurisdiction. Document qualification decisions before shortage-driven urgency forces compromises.

• Flag gray market risk: If a distributor not in your current network offers methylprednisolone acetate inventory, cross-reference against ColdChainCheck data. Entities with no FDA registration, suspended state licenses, or recall history present elevated counterfeit risk during shortages.

• Document allocation decisions: If your organization IS a distributor making allocation decisions, document the methodology used (historical volume ratios, patient acuity tiers, etc.). State boards of pharmacy in California, New York, and Massachusetts have investigated allocation practices during previous shortages for potential discriminatory conduct.

Related Monitoring:

ColdChainCheck tracks FDA enforcement actions, state board sanctions, and product recalls that may signal compliance risk during supply chain stress periods. See DSCSA compliance guides for documentation requirements when onboarding new trading partners under shortage conditions.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Entities should consult qualified legal counsel and verify all compliance requirements with the relevant regulatory authority.